
price close busi octob
biotech discov
invent manufactur commerci medicin
treat seriou diseas
expect broad dupix label uncontrol
expect broad label eosinophil count unlik restrict
expect broad label dupix sever asthma fda help
facilit healthi uptak adopt importantli dupix show statist
signific lower exacerb popul mg
mg dose also eosinophil count part inclusion/exclus criteria
enrol dupix phase liberti asthma quest liberti asthma
ventur studi repres real-world condit view despit fact
patient baselin eosinophil count cells/ul show statist
signific reduct exacerb dose believ statist
signific overal eosinophil popul result broad label
scenario analysi show minim impact stock current valu label
analyz scenario approv dupix asthma broad label
minimum requir eosinophil count minimum eosinophil count cells/
ul minimum eosinophil count cells/ul assum within
uncontrol moderate/sever asthma patient eosinophil count
cells/ul cells/ul cells/ul
minimum requir cells/ul dupix would applic
uncontrol moderate/sever asthma patient cells/ul minimum
requir would applic base analysi believ street
expect broad label approv even label show restrict
eosinophil count stringent condit cells/ul requir would
minim impact share valu yield share decreas valu
eosinophil count driven efficaci data could help differenti dupix xolair
believ dupix lower annual rate asthma exacerb event
patient higher level blood eosinophil count could consider
differenti vs xolair data includ label data packag
interestingli liberti asthma quest liberti asthma ventur trial
mean blood eosinophil count cells/ul thu suggest good
major sever asthma patient would high eosinophil count howev
acknowledg research need understand treat physician view
biomark eosinophil test perform deeper analysi physician
treatment pattern better assess could best util eosinophil count
driven efficaci data differenti dupix xolair
maintain hold rais pt
maintain hold rate rais pt expect like dupix
approv uncontrol persist asthma howev hold view need
focu develop asset would provid full econom compani
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
reduct asthma exacerb across
statist signific driven high eosinophil concern
mg mg dupix dose reduc sever asthma exacerb
placebo overal popul eosinophil count statist
signific liberti asthma quest moder sever asthma studi thu
see need fda restrict use specif eosinophil popul
subpopul analysi base eosinophil stratif
cells/ul show mg mg dupix reduc sever
asthma exacerb event placebo eosinophil subgroup except
cells/ul dose higher eosinophil count group show
among patient eosinophil count cell dose show
statist signific risk reduct exacerb vs placebo also
eosinophil count cell cell neither
dose show statist signific reduct exacerb vs
placebo howev believ statist signific improv lower
rate exacerb overal popul includ eosinophil count
meaning
note patient cells/ul group show lower degre
improv rel placebo rate dose slightli
higher placebo howev given benefit confer overal popul
expect fda place eosinophil level restrict label
figur liberti asthma quest liberti asthma ventur sever asthma exacerb data
hold unchang target price octob
moderate-to-sever asthma liberti asthma quest p-valuep-valueannu rate sever asthma exacerb week tx ratesnratesnratesnratesn eosinophil count cells/ul sever asthma liberti asthma ventur p-valueannu rate sever asthma exacerb week tx ratesnratesn eosinophil count cells/ul reduct oral glucocorticoid baselin least squar mean chang week eosinophil count cells/ul mg mg mg regeneron pharmaceut
reduct sever asthma exacerb also observ liberti
asthma ventur glucocorticoid-depend sever asthma trial mg
dupix arm show consider reduct sever asthma exacerb vs
placebo eosinophil subgroup analysi also show signific reduct sever
asthma exacerb rate activ arm vs placebo across eosinophil count
furthermor also note dupix success led significantli higher
percentag reduct oral glucocorticoid dose baselin overal popul
eosinophil level view data clear demonstr dupix
clinic benefit glucocorticoid-depend sever asthma patient regardless
eosinophil level thu mitig likelihood fda includ minimum eosinophil
level requir label
dupix improv lung function
also extend across eosinophil group
examin forc expiratori volum second data
liberti asthma quest liberti asthma ventur trial saw dupix
improv overal popul trend also observ across
eosinophil group even eosinophil count cells/ul
indic dupix help improv lung function across eosinophil level
thu reduc likelihood fda place eosinophil level restrict label
figur liberti asthma quest liberti asthma ventur forc expiratori volum second data
hold unchang target price octob
moderate-to-sever asthma liberti asthma quest p-valuep-valueratesnratesnratesnratesnbaselin prebronchodil chang week eosinophil count cells/ul sever asthma liberti asthma ventur p-valueratesnratesnbaselin prebronchodil chang week eosinophil count cells/ul mg mg mg regeneron pharmaceut
dupix clinic studi open full rang
eosinophil count
liberti asthma quest trial adult asthma patient enrol
follow key requir persist asthma month per global initi
asthma guidelin medium-to-high-dos inhal glucocorticoid
fluticason propion total daili dose equipot equival
treatment plu two addit control long-act
leukotrien receptor antagonist worsen asthma previou year
led hospit treatment system glucocorticoid day
liberti asthma ventur trial adult asthma patient enrol
follow key requir persist asthma month per global initi
asthma guidelin regular system glucocorticoid mg/day
prednison prednisolon equival high-dos inhal glucocorticoid plu
two addit control
two studi patient enrol minimum baselin eosinophil
count type inflamm biomark requir end expect
fda includ minimum eosinophil count part label thu grant
dupix broad label uncontrol persist asthma
analyz scenario fda decid dupix receiv
restrict label drug indic patient blood eosinophil
count cells/ul cells/ul perform scenario analysi base
follow us eu market model uncontrol persist asthma
hold unchang target price octob
hold unchang target price octob
fy asthma us marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma eosinophil eosinophil eosinophil mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per dose per per annual cost per revenu per us dupilumab demand uncontrol mod/sever asthma- discount rebates- build drawdown us dupilumab revenu uncontrol mod/sever asthma- figur eu uncontrol persist asthma market project
use patient data liberti asthma quest ventur trial
estim eosinophil breakdown uncontrol moderate/sever asthma
patient follow cells/ul cells/ul
cells/ul appl percentag breakdown scenario analysi
yield follow revenu project
hold unchang target price octob
fy asthma eu marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma eosinophil eosinophil eosinophil mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per annual cost per revenu per inventori build drawdown discount rebates- eu dupilumab revenu uncontrol mod/sever asthma- us us project revenu eosinophil cells/ul eosinophil cells/ul label figur scenario analysi dupix label uncontrol persist asthma
current expect broad label dupix uncontrol persist
asthma assess even restrict label minimum eosinophil
requir cells/ul stock could still appreci current
hold unchang target price octob
hold unchang target price octob
oct oct antibodiesregulatori investig new drug applic ind antibodyfda regulatori submiss npdr non-dm patientsregulatori sbla expand indic adolesc year age atop dermatitisfda decis uncontrol persist asthmadata ph one-year data panorama trial npdr innon-dm ph studi osteoarthritisfda decis bla advanc csccdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat figur valuat dcf
hold unchang target price octob
regeneron dcf valuat free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate regeneron
hold unchang target price octob
hold unchang target price octob
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price octob
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand
